Precision oncology holds great promise: for better therapy selection, fewer side effects, and higher success rates, thereby having the potential to improve patient outcomes and cancer care efficiency. However, traditional value frameworks and approval pathways pose challenges which may limit patient access to PO therapies.
This study explores possible solutions, and provides actionable recommendations to maximize PO medicine value.
Read the full study here.
